MeiraGTx shares are on the rise due to the Hologen AI agreement.
MeiraGTx Holdings plc (Nasdaq: MGTX) shares rose by 13% following the announcement of a strategic partnership with Hologen AI aimed at accelerating the Phase 3 development of AAV-GAD for Parkinson's Disease and improving the company's manufacturing processes. Based in London and New York, the clinical-stage gene therapy company revealed the partnership on March 13, 2025, receiving significant financial commitments from Hologen AI. MeiraGTx will receive $200 million in upfront cash and will establish a joint venture named Hologen Neuro AI Ltd., which will receive an additional $230 million from Hologen to fully fund the AAV-GAD program and advance other early-stage clinical programs.
In this groundbreaking collaboration, MeiraGTx will retain a 30% stake in the joint venture and lead all clinical development and manufacturing activities. Hologen will also acquire a minority interest in MeiraGTx’s manufacturing subsidiary, contribute to its annual funding, and leverage AI technologies to optimize MeiraGTx’s proprietary manufacturing processes. The encouraging data from a randomized, sham-controlled clinical bridging study announced in October 2024 has strengthened the potential of AAV-GAD in treating Parkinson's disease. MeiraGTx's CEO, Dr. Alexandria Forbes, expressed excitement about the partnership's potential to enhance the robustness and success probability of the AAV-GAD Phase 3 clinical trial, highlighting its financial significance and the influx of cash it provides to support production operations while maintaining significant equity value in the late-stage Neuro-AI company. The transactions are expected to close in the second quarter of 2025, subject to customary closing conditions, and have been positively received by investors, as reflected in the increase in MeiraGTx's stock price, which indicates growing confidence in the company's advanced prospects for developing treatments for neurological disorders.
This article has been created with the support of AI, translated, and reviewed by an editor. For more information, please refer to our Terms and Conditions.